Integra LifeSciences gets "buy" rating — 5 quick facts

Spinal Tech

Integra LifeSciences achieved a "buy" recommendation from a few different brokerages, according to a Mideast times report.

There are seven ratings firms that have a "buy" for Integra, with two equities analysts have the stock rated at a "hold"

 

Here are five quick facts about Integra LifeSciences stock:

 

• Average on-year target price among covering brokers is $61
• Barclays analysts raised their price target from $50 to $60
• Oppenheimer analysts reiterated their "outperform" rating and set a $62 price target
• Argus raised their price target from $55 to $61 with a "buy" rating on Feb. 13
• Integra has a $1.9 billion market cap and 58.26 price-to-earnings ratio

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers